Phathom PharmaceuticalsPHAT +3.73%23 Days Payable is 43.16 as of Mar. 2026, which is 92% below its 10-year median of 528.94. GuruFocus rates PHAT with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 707 Biotechnology companies, Phathom Pharmaceuticals ranks worse than 60.68% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Phathom Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phathom Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Phathom Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Phathom Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phathom Pharmaceuticals (PHAT) has a Days Payable of 43.16 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Phathom Pharmaceuticals and its competitors. This is 92% below median its historical median of 528.94. Over the past decade, Phathom Pharmaceuticals' Days Payable has ranged from 66.32 to 24,695.42. According to the industry distribution chart, Phathom Pharmaceuticals ranks #429 out of 707 companies in the Biotechnology industry, placing it in the top 60.7%.
Is Phathom Pharmaceuticals' Days Payable too high?
Phathom Pharmaceuticals' current Days Payable of 43.16 is 92% below median its 10-year median of 528.94. Over the past 10 years, this metric has ranged from a low of 66.32 to a high of 24,695.42. The Biotechnology industry median Days Payable is 113.76. Phathom Pharmaceuticals' value of 43.16 is 62.1% below this industry median. Based on the distribution chart, Phathom Pharmaceuticals ranks #429 out of 707 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Phathom Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' Days Payable compare to AURA and RLMD?
According to the Biotechnology industry distribution chart, Phathom Pharmaceuticals ranks #429 out of 707 companies for Days Payable. This places Phathom Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.76. Phathom Pharmaceuticals' value of 43.16 is 62.1% below this benchmark. Historically, Phathom Pharmaceuticals' own Days Payable has ranged from 66.32 to 24,695.42 over the past decade. While the company's 10-year median is 528.94 vs. the industry median of 113.76, Phathom Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phathom Pharmaceuticals's current Days Payable of 43.16 is 62.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Phathom Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phathom Pharmaceuticals's current Days Payable is 43.16, which is 92% below median its own 10-year median of 528.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Phathom Pharmaceuticals (PHAT) has a current Days Payable of 43.16. The current Days Payable is 43.16, which is 92% below median its 10-year median of 528.94 and 62.1% below the Biotechnology industry median of 113.76. Phathom Pharmaceuticals' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current Days Payable is 43.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
23GF Score
Get the complete analysis for PHAT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAT has been successfully added to your 
